Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
about
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Applications of CYP450 testing in the clinical settingFrom pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resourceCombinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical UtilityImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsEconomic evaluations of personalized medicine: existing challenges and current developmentsPersonalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics and cardiovascular diseasePharmacogenomics discovery and implementation in genome-wide association studies eraStroke genetics: prospects for personalized medicineClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationPharmacogenomics of hypertension and heart diseaseUse of contemporary genetics in cardiovascular diagnosisRespiratory review of 2014: pulmonary thromboembolismAdvantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics TestingThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityPharmacogenomics: personalizing pediatric heart transplantationEffect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysisPharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next DecadeAnalysis of Genetic Variation in CYP450 Genes for Clinical ImplementationWarfarin Pharmacogenetics: New Life for an Old DrugA New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish PopulationIncidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are AvailableThe Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyGenetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomicsIntegrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokineticsProgress towards the integration of pharmacogenomics in practiceElectronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.Future translational applications from the contemporary genomics era: a scientific statement from the American Heart AssociationOpen access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicineUse of genetic data to guide therapy in arterial disease.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Towards the clinical implementation of pharmacogenetics in bipolar disorder.The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Pharmacogenetics of warfarin: challenges and opportunities.
P2860
Q24567778-A00DB1B6-8E15-4C0B-BC5D-DA40BC2D7726Q24621760-4D706BA4-7757-422B-B157-E587FA4490B9Q24632079-C30F5B55-8805-4274-B2CF-B1F442700274Q26775813-9BEAFBA9-5363-47C5-B2F6-87F3910AFA0AQ26787099-153EC32F-8C58-4775-B049-A1F3BC9D797DQ26797183-787DC517-FFEA-4773-858E-A4F6C6E229AFQ26822796-C67AF3F2-42F7-4605-A469-944EC9DB3E63Q26823542-90BA1E1E-5BC6-4821-A6BF-0E1D248ED34AQ26997380-EE40F4DC-D046-4AAC-8F0D-2235190AAAE9Q27001573-A2DC4787-FAFD-4DD0-AEB6-93DCFB924A9DQ27006885-97AFAB71-C18A-4972-9CB4-D096C7564C7CQ27011524-4B3FB6C1-3641-41C1-AD69-7328AB6F7EC8Q27015722-0EB46521-B55F-4A58-8C33-7BFDEF0533DFQ27025306-7C64170C-4F39-4A33-996A-A30B7C6B496CQ27028131-B9099C03-B9D1-40FD-8764-F073DC413ED5Q28079766-41907DFA-C1A5-46E6-B047-C30BA3B3B4F8Q28080256-2207C427-73E8-4614-A8FF-CF6A4222755DQ28081200-7224955B-FBE2-4CD9-A944-F1DA1DF902C8Q28276605-36C24CB8-C962-4A18-8CD2-8384A49B6F2EQ28392069-1480E943-1CCD-4C32-AE79-E4648DF48CDEQ28468449-F858A73B-CC09-486F-A7ED-EF08E56BAB83Q28468726-CB1D9E06-E0CD-47DD-8736-713C00AF7EE1Q28550740-6BC7362E-9D37-4843-9C1E-E3A3FDA48977Q28552832-15B77653-88D0-477C-B6C2-F56CB1F46FEDQ28553937-36FE6875-00BE-4CDC-ABC9-F32B876C53FFQ28601852-BCFD78E8-148D-47BE-A79F-F7454E49E863Q28650281-B66F707F-5042-42C0-B9E6-2042C10FF7C0Q28652270-BEAAA3F5-633B-4F6A-8223-6D3747052E44Q30234897-A6E04918-179E-4812-BCF9-187B45A56AC5Q30359686-625C12CD-E228-4736-8FC5-2FE6EFAB1406Q30487537-5AFEAD4B-D105-4154-A6B5-C777D348D96CQ30978916-532098E9-E505-46B8-BEC8-D9A01778B578Q31058146-0B3FA602-0B01-423F-8728-EAF19E280F3CQ31131437-463BBD91-4550-4A40-9D18-2D39FAB93962Q33688133-68D55F85-8E08-471D-BDC8-D236F7023AAEQ33707218-35A996B1-E884-478B-80C2-35102ED7A332Q33770184-1ED90471-CF7B-4989-A661-44A5929CAB88Q33782314-42601196-73F4-43C9-88C2-DD171ED74147Q33792154-1ADDFF2B-6127-414E-B406-94364100AF4DQ33819050-B9C78B3E-DF6E-4D82-83FA-DD02B71DE507
P2860
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@ast
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@en
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@nl
type
label
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@ast
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@en
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@nl
prefLabel
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@ast
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@en
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@nl
P2093
P2860
P50
P3181
P356
P1476
Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing
@en
P2093
J A Johnson
J L Anderson
R B Altman
S E Kimmel
P2860
P3181
P356
10.1038/CLPT.2011.185
P407
P577
2011-10-01T00:00:00Z